ENSC Stock Price | Ensysce Biosciences Inc P/E, Revenue, EPS, & Forecasts

Ensysce Biosciences Inc • ENSC

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Ensysce Biosciences Inc

Ticker

ENSC

Trading on

NASDAQ

ISIN

US2936021086

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. D. Lynn Kirkpatrick Ph.D.

Headquarters

7946 Ivanhoe Avenue, La Jolla, CA, United States, 92037

Employees

Website

ensysce.com

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Metrics

BasicAdvanced

Market cap

$5.8M

P/E ratio

EPS

-$6.35

Dividend Yield

0.00%

Beta

1.15

Forward P/E ratio

0.95

EBIDTA

$-24.2M

Ex dividend date

Price & volume

Market cap

$5.8M

Average daily volume

0.1M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

0.95

PEG ratio

Trailing P/E

Price to sales

1.29

Price to book

4.8

Earnings

EPS

-$6.35

EPS estimate (current quarter)

-$0.93

EPS estimate (next quarter)

-$0.72

EBITDA

$-24.2M

Revenues (TTM)

$4.5M

Revenues per share (TTM)

$2.32

Technicals

Beta

1.15

52-week High

$10.96

52-week Low

$1.46

50-day moving average

$2.14

200-day moving average

$2.54

Short ratio

1.04

Short %

2.34%

Management effectiveness

ROE (TTM)

-294.39%

ROA (TTM)

-109.79%

Profit margin

-244.49%

Gross profit margin

$-6.1M

Operating margin

-758.68%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

-85.60%

Share stats

Outstanding Shares

3.6M

Float

3.1M

Insiders %

0.29%

Institutions %

9.93%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$19.23

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$2.90

-$1.95

-48.72%

Q4 • 24Missed

-$1.39

-$1.53

9.15%

Q1 • 25Beat

-$0.79

-$1.09

27.52%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$1.4M

$-1.7M

-126.39%

Q2 • 25

$0.5M

$-3.7M

-756.26%

Q3 • 25

-64.04%

115.14%

498.35%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$5.6M

$2.5M

45.10%

Q2 • 25

$3.2M

$2.3M

72.49%

Q3 • 25

-42.96%

-8.32%

60.73%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-2.7M

$1.9M

$-2.7M

Q2 • 25

$-1.9M

$1.5M

$-2M

Q3 • 25

-31.06%

-22.21%

-26.49%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Ensysce Biosciences Inc share?

Ensysce Biosciences Inc shares are currently traded for undefined per share.

How many shares does Ensysce Biosciences Inc have?

Ensysce Biosciences Inc currently has 3.6M shares.

Does Ensysce Biosciences Inc pay dividends?

No, Ensysce Biosciences Inc doesn't pay dividends.

What is Ensysce Biosciences Inc 52 week high?

Ensysce Biosciences Inc 52 week high is $10.96.

What is Ensysce Biosciences Inc 52 week low?

Ensysce Biosciences Inc 52 week low is $1.46.

What is the 200-day moving average of Ensysce Biosciences Inc?

Ensysce Biosciences Inc 200-day moving average is $2.54.

Who is Ensysce Biosciences Inc CEO?

The CEO of Ensysce Biosciences Inc is Dr. D. Lynn Kirkpatrick Ph.D..

How many employees Ensysce Biosciences Inc has?

Ensysce Biosciences Inc has 7 employees.

What is the market cap of Ensysce Biosciences Inc?

The market cap of Ensysce Biosciences Inc is $5.8M.

What is the P/E of Ensysce Biosciences Inc?

The current P/E of Ensysce Biosciences Inc is null.

What is the EPS of Ensysce Biosciences Inc?

The EPS of Ensysce Biosciences Inc is -$6.35.

What is the PEG Ratio of Ensysce Biosciences Inc?

The PEG Ratio of Ensysce Biosciences Inc is null.

What do analysts say about Ensysce Biosciences Inc?

According to the analysts Ensysce Biosciences Inc is considered a buy.